title: mTORC1 activation in childhood ependymoma and response to sirolimus.
abstract: Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient's tumor.
authors.affiliation: Department of Pediatrics, University of Texas Southwestern Medical School at Dallas, Dallas, TX 75390, USA. Daniel.Bowers@utsouthwestern.edu
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Bowers
authors.forename: Blanka
authors.initials: B
authors.lastname: Kucejova
authors.forename: Linda
authors.initials: L
authors.lastname: Margraf
authors.forename: Lynn
authors.initials: L
authors.lastname: Gargan
authors.forename: James
authors.initials: J
authors.lastname: Brugarolas
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002675:Child, Preschool; D004806:Ependymoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D038601:Ribosomal Protein S6 / Q000378:metabolism; D012694:Serine / Q000378:metabolism; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D007166:Immunosuppressive Agents; D038601:Ribosomal Protein S6; D012694:Serine; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus